Higher versus Lower Continuous Renal Replacement Therapy Intensity in Critically ill Patients with Liver Dysfunction
Zachary O'Brien, Alan Cass, Louise Cole, Simon Finfer, Martin Gallagher, Colin McArthur, Shay McGuiness, John Myburgh, Rinaldo Bellomo, Johan Martensson
Blood Purification | KARGER | Published : 2018
Awarded by National Health and Medical Research Council (NHMRC) of Australia
Awarded by Health Research Council (HRC) of New Zealand
This study was supported by grants from the National Health and Medical Research Council (NHMRC) of Australia (grant 352550) and Health Research Council (HRC) of New Zealand (grant 06-357). The study sponsors had no role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication.Professor Alan Cass received funding from the Australian National Health and Medical Research Council; and received grant support from Roche and Gambro. Professor Rinaldo Bellomo received consulting fees as an advisor for Gambro; and consulted for Gambro, Biosite, Abbott, and Philipps. Dr. Gallagher received honoraria/speaking fees from Roche. Dr. Martensson received travel support to present research results at scientific meetings from Gambro; and received funding from Karolinska Institutet. The remaining authors have not disclosed any potential conflicts of interest.The George Institute has received research funding from Servier, Novartis, Eisai, Merck, Sharp and Dohme, Pfizer Australia, Fresenius Kabi Deutschland GmbH, and Sanofi Aventis.